TNF-α mediates mitochondrial uncoupling and enhances ROS-dependent cell migration via NF-κB activation in liver cells  by Kastl, L. et al.
FEBS Letters 588 (2014) 175–183journal homepage: www.FEBSLetters .orgTNF-a mediates mitochondrial uncoupling and enhances
ROS-dependent cell migration via NF-jB activation in liver cells0014-5793/$36.00  2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.febslet.2013.11.033
Abbreviations: CCCP, carbonyl cyanide m-chlorophenyl hydrazine; HBV,
hepatitis B virus; HCV, hepatitis C virus; H2DCF-DA, dichloroﬂuorescein diacetate;
NAC, N-acetylcysteine; ROS, reactive oxygen species; TMRE, tetramethylrhodamine
ethyl ester; TNF-a, tumor necrosis factor-alpha
⇑ Corresponding author. Fax: +49 6221 411715.
E-mail address: k.guelow@dkfz.de (K. Gülow).L. Kastl a, S.W. Sauer b, T. Ruppert b, T. Beissbarth c, M.S. Becker a, D. Süss a, P.H. Krammer a, K. Gülow a,⇑
aDivision of Immunogenetics, Tumour Immunology Program, German Cancer Research Center (DKFZ), Heidelberg, Germany
bDepartment of General Pediatrics, Division of Inborn Metabolic Diseases, University Children’s Hospital, Heidelberg, Germany
cDepartment of Medical Statistics, University of Goettingen, Goettingen, Germanya r t i c l e i n f o
Article history:
Received 19 August 2013
Revised 19 November 2013
Accepted 25 November 2013
Available online 4 December 2013
Edited by Quan Chen
Keywords:
Hepatocellular carcinoma (HCC)
Hepatocytes
Liver cancer
Mitochondria
NF-jB
Reactive oxygen species (ROS)
TNF-aa b s t r a c t
Development of hepatocellular carcinoma (HCC) is accompanied by a continuous increase in
reactive oxygen species (ROS) levels. To investigate the primary source of ROS in liver cells, we used
tumor necrosis factor-alpha (TNF-a) as stimulus. Applying inhibitors against the respiratory chain
complexes, we identiﬁed mitochondria as primary source of ROS production. TNF-a altered
mitochondrial integrity by mimicking a mild uncoupling effect in liver cells, as indicated by a
40% reduction in membrane potential and ATP depletion (35%). TNF-a-induced ROS production
activated NF-jB 3.5-fold and subsequently enhanced migration up to 12.7-fold. This study identiﬁes
complex I and complex III of the mitochondrial respiratory chain as point of release of ROS upon
TNF-a stimulation of liver cells, which enhances cell migration by activating NF-jB signalling.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Human hepatocellular carcinoma (HCC) is the 5th most com-
mon cancer occurring worldwide with prevalence in men and
higher incidence rates in developing than developed countries
[1]. Whereas about 80% of primary liver cancers develop through
underlying Hepatitis B (HBV) and Hepatitis C (HCV) infections,
other risk factors include smoking, diabetes, overweight and aﬂa-
toxin exposure in diet. Apart from known risk factors, several
molecular mechanisms have been elucidated that contribute to
HCC. This comprises alterations in signalling pathways, oncogene
activation or decreased tumour suppressor gene expression.
Reactive oxygen species (ROS) such as superoxide anions are
byproducts of respiration, generated by mitochondria. In recent
years it became evident that ROS are not only byproducts of respi-
ration but also can act as second messengers to activate signalling
pathways and hence lead to alterations in gene expression [2–4].Increased ROS levels are commonly described in enhanced liver
disease and HCC [5–7]. However, the primary source of ROS gener-
ation in liver disease has not yet been fully elucidated. In addition,
whether ROS act as second messenger in altering signalling path-
ways or expression of tumour suppressors, therefore reinforcing
the development of HCC, remains to be elucidated.
HCC often develops through underlying infections accompanied
by activation of the immune system. Increased expression of
pro-inﬂammatory cytokines such as tumor necrosis factor-alpha
(TNF-a) is associatedwith hepatocyte apoptosis but is also essential
in hepatocyte proliferation [8] and liver regeneration [9]. By bind-
ing to its receptors (TNFR1/TNFR2), TNF-a activates two different
signalling cascades either leading to apoptosis or proliferation
[10]. In the latter case, TNF-a-stimulation leads to IKK activation
resulting in IrBa phosphorylation and subsequent IrB degradation.
NF-rB translocates into the nucleus inducing downstream gene tar-
gets including the pro-inﬂammatory chemokine IL-8. Activation of
NF-rB ultimately results in enhanced proliferation and cell survival.
In addition to its signalling modulatory effects, TNF-a is described
to induce ROS production in mitochondria as well as to alter mito-
chondrial function by impairing membrane permeability [11,12].
Here, we investigated TNF-a-induced ROS production in liver
cells and identiﬁed the respiratory chain as primary source of
176 L. Kastl et al. / FEBS Letters 588 (2014) 175–183ROS production. TNF-a-induced ROS production led to activation
of NF-rB and enhanced cell migration of liver cells.
2. Materials and methods
Materials and methods are given in the Supplementary Data.
3. Results
3.1. Mitochondria are the main source of ROS production in liver cells
To identify the source of ROS production in liver cells, we estab-
lished an in vitro cell system using the cytokine TNF-a to stimulate
primary murine hepatocytes and two liver cancer cell lines
(Hepa1–6 [murine], Huh-7 [human]). Different concentrations of
TNF-a induced ROS in all cell types, however, 50 ng/ml TNF-a
was most effective, inducing a 150% increase in ROS (Fig. 1A;
Supplementary Fig. S1A). Of note, TNF-a did not induce cell death
at concentrations used (data not shown). 50 ng/ml TNF-awas then
applied throughout all experiments. Using the antioxidant
N-acetylcysteine (NAC), TNF-a-induced ROS was dose-dependently
inhibited in primary murine hepatocytes by 42.1% (±6.0; P = 0.002)
and 57.8% (±4.4; P < 0.001), respectively (Fig. 1A) and also in Huh-7
cells (Supplementary Fig. S1A) and Hepa1–6 cells (data not
shown). In addition, ROS was scavenged by the water soluble
Vitamin E derivate Trolox (data not shown). To determine the
primary source of the ROS signal, a variety of different inhibitors
of the respiratory chain were applied to primary murine hepato-
cytes and liver cancer cells. The speciﬁc complex I inhibitor of
the respiratory chain, Rotenone, dose-dependently blocked the
TNF-a-induced ROS signal in hepatocytes by 71.8% (±18.4;
P = 0.007) and 96.6% (±6.8; P < 0.001), respectively (Fig. 1B). Since
primary hepatocytes were not transfectable in culture, this result
was validated in Hepa1–6 and Huh-7 cells using speciﬁc siRNAs
against NDUFAF1, an essential assembly factor for complex I [13].
NDUFAF1 siRNA transfection also inhibited the TNF-a-induced ROS
signal by over 95% (±12.1; P < 0.001; Fig. 1C; Supplementary
Fig. S1B and C). In addition, ROS production was also dose-
dependently inhibited by the complex III inhibitor Antimycin A
(Fig. 1B; Supplementary Fig. S1B). Here, ROS production generated
by TNF-a-stimulation was reduced to 36.1% (±20.6) and 17.7%
(±11.9; P = 0.02), respectively (Fig. 1B). Using Antimycin A at a
concentration of 1 lg/ml resulted in slight toxicity, hence 0.5 lg/
ml was used for subsequent experiments. Using a pool of siRNAs
against the complex III assembly factor BCS1L [14], this also
reduced TNF-a-induced ROS generation in Hepa1–6 cells (54.3%,
±4.1; P < 0.001) and Huh-7 cells (Fig. 1C; Supplementary
Fig. S1C). To further demonstrate the important role of complex I
and complex III in TNF-a-mediated ROS production in liver cells,
we used inhibitors against complex II, complex IV and the
F0F1-ATPase. As expected, the complex II inhibitor Atpenin A5 sig-
niﬁcantly reduced TNF-a-induced ROS production. Of note, from
complex II additional electrons are delivered to complex III via
the quinone pool. In contrast Azide (complex IV inhibitor) and
Oligomycin (ATPase inhibitor) did not show any effect
(Supplementary Fig. S1D). Reducing TNF-a-induced ROS produc-
tion using speciﬁc chemical inhibitors and siRNA against
components of the respiratory chain identiﬁes the mitochondrial
respiratory chain, involving complex I and III, as primary source
of TNF-a-speciﬁc ROS production in liver cells.
3.2. TNF-a mimics a mild uncoupling effect on mitochondria in liver
cells
Mitochondria were identiﬁed as source of TNF-a-induced ROS
production. Therefore, we further investigated the inﬂuence ofTNF-a onmitochondria. TNF-a-treatment led to a signiﬁcant reduc-
tion in membrane potential in murine hepatocytes (63% ±3.5;
P < 0.001; Fig. 2A). In addition, TNF-a treatment reduced ATP pro-
duction in murine hepatocytes by 34.8% (±2.8; P = 0.006) (Fig. 2B).
Reduction in membrane potential as well as ATP depletion are de-
scribed phenomena in mitochondrial uncoupling [15]. To further
investigate alterations in mitochondrial physiology in hepatocytes
we studied the activities of respiratory chain complexes, electron
ﬂux and mitochondrial respiration. Whereas no differences were
seen after TNF-a treatment in the activity of complex I, II, III and
IV and in electron ﬂux from complex I to complex III (data not
shown), an increased electron ﬂux of 19.7% (±28.7; P = 0.03) from
complex II to complex III was observed upon TNF-a-treatment in
murine hepatocytes (Fig. 2C). Also, mitochondrial oxygen consump-
tion was increased after TNF-a treatment (173.4% ±28.7) compared
to control-treated cells (60.5 ± 8.6; P = 0.02; Fig. 2D). Here, we show
an alteration of mitochondrial integrity by TNF-a-treatment in liver
cells that mimics mitochondrial uncoupling events as seen with the
uncoupler carbonyl cyanide m-chlorophenyl hydrazine (CCCP)
(Fig. 2A and B). Therefore, we identify that TNF-a treatment leads
to a mild uncoupling of mitochondrial respiration in liver cells.
3.3. TNF-a-induced ROS production alters cell migration in liver cells
The previous experiments showed that TNF-a induces ROS
production and alters mitochondrial function. Therefore, we inves-
tigated how TNF-a-mediated ROS production physiologically
affects liver cells. Due to the non-proliferative capacity of primary
hepatocytes in cell culture, we performed wound healing assays
in Hepa1–6 cells after TNF-a-treatment with or without Rotenone
and Antimycin A. Migratory potential was then evaluated as a
measure of closure of the gap within a 16 h time frame (Fig. 3A).
TNF-a increased migration in Hepa1–6 cells compared to control-
treated cells (4.6-fold ±3.0) and treatment with Rotenone inhibited
this effect (4.2-fold decrease ±0.1) (Fig. 3A). Similar results were
obtained using Antimycin A (Fig. 3B). Here, TNF-a increased migra-
tion in Hepa1–6 cells by 12.7-fold (±3.8; P = 0.04) and additional
treatment with Antimycin A almost completely reversed this effect
(14.8-fold decrease ±0.1; P = 0.04) (Fig. 3B). To ensure that the
effects seen with Rotenone and Antimycin A are not due to cytotox-
icity, the ROS scavenger NAC and Trolox were used as control. Also,
with NAC (Fig. 3; Supplementary Fig. S2) and Trolox (data not
shown), migration was inhibited (19.6-fold decrease ±0.3;
P = 0.04). Thus, complex I and complex III activity plays a crucial
role in controlling the proliferative capacity of liver cells.
3.4. NF-rB signalling is affected by TNF-a-induced mitochondrial ROS
production
TNF-a is known to activate the ROS-dependent transcription
factor NF-rB [2], which in turn leads to enhanced cell growth
and proliferation. We therefore investigated the expression of
NF-rB-target genes after TNF-a-treatment. The NF-rB-dependent
target genes Cxcl1, IrBa and A20 were upregulated upon TNF-a
treatment in murine hepatocytes (Fig. 4A and C). This increase in
mRNA levels could be reversed by either pre-treating cells with
NAC (Supplementary Fig. S3A) or Rotenone (Fig. 4A) and Antimycin
A (Fig. 4C), respectively. In addition, TNF-a treatment also in-
creased the expression of IL-8 and IrBa in Huh-7 cells and this
was also reversed by both Rotenone and Antimycin A (Supplemen-
tary Fig. S3B). In HCC, the NF-rB target gene IL-8 is involved in reg-
ulation of the expression of genes involved in invasion and
metastasis [16]. To also associate our ﬁndings with a clinical set-
ting, we investigated human tissue samples. Comparing expression
data of 67 human HCC with 10 normal control liver tissues [17]
(GEO database, accession GSE50579), a signiﬁcant (t-test,
Fig. 1. Mitochondria are the main source of TNF-a-induced ROS production in liver cells. (A) ROS generation after TNF-a-stimulation was measured in primary murine
hepatocytes and Hepa1–6 cells using H2DCF-DA after administration of different concentrations of TNF-a for 1 h. In addition, primary murine hepatocytes were pre-treated
with NAC for 30 min and subsequently treated with TNF-a for 1 h. H2DCF-DA-only or NAC-only treated cells served as control and % decrease is presented relative to TNF-a-
only treated cells. (B) The source of TNF-a-mediated ROS production was investigated in primary hepatocytes using Rotenone (Rot) and Antimycin A (AA). Primary murine
hepatocytes were pre-treated with different Rotenone and Antimycin A concentrations for 30 min, respectively, and subsequently treated with TNF-a for 1 h. H2DCF-DA-only
or Rotenone-only or Antimycin A-only treated cells served as control and % decrease is presented relative to TNF-a-only treated cells. (C) Hepa1–6 cells were transfected with
siRNAs against NDUFAF1 and BCS1L and TNF-a-induced ROS production was measured. H2DCF-DA-only stained cells served as control. ROS measurements were performed
as in (B). All experiments were performed in triplicate with three technical replicates per sample. ⁄P < 0.05; ⁄⁄⁄P < 0.001.
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Fig. 2. TNF-a mimics an uncoupling effect on mitochondria in liver cells. (A) Mitochondrial membrane integrity was measured using TMRE. Mitochondrial depolarisation is
presented as MFI and alterations in ﬂuorescence were measured after administration of TNF-a for 1 h. TMRE-only stained cells were used as control. CCCP was used as
positive control. (B) Intracellular ATP content in primary murine hepatocytes in TNF-a-treated cells (50 ng/ml, 1 h) compared to control-treated cells. Results are shown as %
increase relative to control, where control cells were set to 100%. CCCP was used as positive control. (C) Electron ﬂux from complex II (CII) to complex III (CIII) was measured
in primary murine hepatocytes after 1 h TNF-a treatment (50 ng/ml). Results are shown as complex activity in % relative to control-treated cells. (D) Mitochondrial oxygen
consumption was measured after 1 h TNF-a treatment (50 ng/ml) compared to control-treated cells. Results are shown as mitochondrial oxygen consumption in %, where
mitochondrial oxygen consumption was calculated by subtracting the ‘‘NaN3-insensitive oxygen consumption rate’’ from the ‘‘total oxygen consumption rate’’. All
experiments were performed in triplicate. ⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001.
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was observed. To further validate a TNF-a – dependent activation
of NF-rB due to ROS production, we used a NF-rB luciferase repor-
ter system. Here, TNF-a activated NF-rB, which was almost com-
pletely inhibited by pre-treating the cells with speciﬁc ROS
scavengers or siRNAs against important assembly factors for com-
plexes of the respiratory chain (Supplementary Fig. S3C). This dem-
onstrates a complex I- and/or complex III-dependent activation of
the NF-rB pathway upon stimulation with TNF-a in liver cells.
We also investigated NF-rB-activation on protein level. TNF-a-
stimulation increased IrBa and P65 phosphorylation after 10 min
(Fig. 4B and D). Both, Rotenone and Antimycin A reversed this acti-
vation, further validating our ﬁndings of mitochondrial alterations
and ROS-dependent NF-rB-activation upon TNF-a-treatment
(Fig. 4B and D).
3.5. TNF-a-induced ROS production enhances cellular migration via
NFrB-activation
We reasoned that increased cell migration was due to the acti-
vation of NF-rB. To test this hypothesis, Hepa1–6 cells were pre-
treated with an NF-rB-activation inhibitor, followed by TNF-a-
stimulation and the migration potential was assessed by wound
healing. Application of an NF-rB-activation inhibitor reversed
TNF-a-induced migration (6.5-fold ±2.8) in Hepa1–6 cells by 6.5-
fold (±0.04) (Fig. 5A) to a similar extent compared to treatment
with the anti-oxidant NAC (Supplementary Fig. S2).4. Discussion
In the present study, we show that TNF-a-induced ROS in liver
cells is mainly generated by mitochondria and that ROS release is
exerted by complex I and/or complex III of the respiratory chain.
TNF-a stimulation altered mitochondrial integrity by decreasing
mitochondrial membrane potential and ATP synthesis, by increas-
ing electron ﬂux from complex II to complex III as well as by
enhancing mitochondrial respiration. In addition, we showed that
TNF-a-induced ROS production leads to NF-rB-activation and
hence activation of pro-survival signals which increased cellular
migration of liver cells.
TNF-a is a pro-inﬂammatory cytokine that was ﬁrst described
as product of cytotoxic activity of lymphocytes [18]. TNF-a, and
other members of the TNF-superfamily are secreted by T and B
cells, monocytes and macrophages. By binding to the receptors
TNFR1/TNFR2, TNF-a can either activate pro-apoptotic or anti-
apoptotic signalling [19]. Cytokines, including TNF-a, are released
due to response to a variety of different cellular events such as
inﬂammation and carcinogen-induced injury [20]. As an immune
cell-enriched organ, the liver is prone to inﬂammation and it is
established that chronic infections with HBV and HCV are major
risk factors for the development of HCC [21]. In line with this, in-
creased TNF-a expression as well as elevated levels of TNFR1/
TNFR2 are described to be elevated in HCC patients [22–24]. Apart
from its pro-inﬂammatory actions, there is also evidence that TNF-
a production increases oxidative stress in a variety of different
Fig. 3. TNF-a-induced ROS production alters cell migration in liver cells. Cellular migration was measured using wound healing assays. Hepa1–6 cells were either pre-treated
with Rotenone (A) or Antimycin A (B), followed by 16 h TNF-a stimulation. (A, upper panel) Representative image. (A, lower panel) Mean quantiﬁcation of Hepa1–6 cells
treated with Rotenone and TNF-a (n = 3). (A, lower panel) Quantiﬁcation of one representative experiment of Hepa1–6 cells treated with Rotenone and TNF-a. (A, lower
panel) Mean quantiﬁcation of Hepa1–6 cells treated with NAC and TNF-a (n = 3). (B, upper panel) Representative image. (B, lower panel) Mean quantiﬁcation of Hepa1–6 cells
treated with Antimycin A and TNF-a (n = 3). (B, lower panel) Quantiﬁcation of one representative experiment of Hepa1–6 cells treated with Antimycin A and TNF-a. (B, lower
panel) Mean quantiﬁcation of Hepa1–6 cells treated with NAC and TNF-a (n = 3). The open area of the gap was recorded at time point 0 and after 16 h TNF-a treatment.
Migration was expressed as fold change of wound closure where differences in wound closure were calculated relative to control (DMSO-treated cells). Experiments were
performed in triplicate with at least three technical replicates per sample. ⁄P < 0.05.
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murine hepatocytes and liver cancer cells already after short-termtreatment with TNF-a. However, in contrast to many reports, TNF-
a-produced ROS did not induce cell death, which resembles the
Fig. 4. NF-rB signalling is affected by TNF-a-induced mitochondrial ROS production. Cxcl1, IrBa and A20 mRNA expression was measured by qRT-PCR in TNF-a-treated cells
with or without pre-treatment with Rotenone (A) or Antimycin A (C), respectively. GAPDH was used for normalisation. The results are expressed as fold induction (±S.E.M.)
relative to control. DMSO-treated cells, Rotenone-only or Antimycin A-only treated cells served as control (=1). All experiments were repeated in duplicate with cDNA
synthesized from three independent RNA extractions. pIrBa, total IrBa, pP65 and total P65 were measured in TNF-a-treated cells with or without pre-treatment with
Rotenone (B) or Antimycin A (D) for indicated time points. (Upper panel) Representative Western blots are shown. (Lower panel) Protein expression was calculated relative to
total IrBa and total P65 expression, respectively. Results are shown as fold change (±S.E.M.). DMSO-treated cells, Rotenone-only or Antimycin A-only treated cells served as
control (=1). All experiments were repeated in triplicate. ⁄P < 0.05; ⁄⁄⁄P < 0.001.
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ROS as second messenger. To elucidate the primary source of
TNF-a-induced ROS production in liver cells, we applied inhibitors
against different complexes of the respiratory chain and identiﬁed
mitochondria as primary source of ROS production with complex I
and/or complex III as key points of ROS generation. Several studies
identiﬁed mitochondria as main source of ROS production in differ-
ent cellular processes. Whereas complex I was identiﬁed as pri-
mary point of release in activation-induced ROS generation inhuman T cells [3], complex III-dependent ROS generation was
essential to initiate adipocyte differentiation [30]. We found com-
plex I and/or complex III as points of ROS release in our experimen-
tal system, which indicates a cell type-dependent and stimulus-
speciﬁc involvement of different complexes of the respiratory
chain in ROS-dependent signalling. However, mitochondrial ROS
sources can crosstalk to other ROS sources such as NADPH oxidases
[3]. Hence other ROS sources may also be activated upon TNF- a in
liver cells.
Fig. 5. TNF-a-induced ROS production enhances cellular migration via NF-jB-activation. Cells were pre-treated with NF-rB-activation inhibitor (5 lM), followed by 16 h
TNF-a stimulation. (A, upper panel) Representative image. (A, lower panel) Mean quantiﬁcation of Hepa1–6 cells treated with NF-rB-activation inhibitor and TNF-a (n = 3).
(A, lower panel) Quantiﬁcation of one representative experiment of Hepa1–6 cells treated with NFrB-activation inhibitor and TNF-a. The open area of the gap was recorded at
time point 0 and after 16 h TNF-a treatment. Migration was expressed as fold change of wound closure where differences in wound closure were calculated relative to control
(DMSO-treated cells). Experiments were performed in triplicate with at least three technical replicates per sample. ⁄P < 0.05. (B) Schematic representation of the proposed
mechanism of ROS- and NF-rB-dependent migration of liver cells.
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chondria by decreasing membrane potential and ATP synthesis, by
accelerating electron ﬂux from complex II to complex III and by
enhancingmitochondrial respiration (Fig. 5B). Particularly, a break-
down of the mitochondrial membrane potential and ATP depletion
are per deﬁnition indicators of mitochondrial uncoupling, which is
described for uncouplers of oxidative phosphorylation, such as CCCP[15,31,32]. In addition, many studies also observed enhanced elec-
tron ﬂux and increased mitochondrial respiration upon uncoupling
[33–35]. Therefore, we identify TNF-a as a mild uncoupler in liver
cells. In line with this, TNF-a was described to alter mitochondrial
integrity and mitochondrial electron transfer was completely
diminished by TNF-a in mouse ﬁbroblasts [36]. Also, mitochondrial
ultrastructure was degenerated [12] and uncoupling respiration of
182 L. Kastl et al. / FEBS Letters 588 (2014) 175–183livermitochondriawas shownprior to the cytotoxic effects of TNF-a
[11]. Hereby, TNF-a may activate different receptor-dependent
pathways for example via RIP [37] or other so far not identiﬁed
molecules.
Pro-survival signals mediated by TNF-a may indicate a role of
NF-rB-activation [19]. NF-rB-activation is a described phenome-
non in a variety of different cancers, including cancers of lymphoid
tissues and solid tumours such as HCC [38]. In the present study,
we showed that TNF-a activates NF-rB in a ROS-dependent man-
ner, since both the complex I inhibitor Rotenone and the complex
III inhibitor Antimycin A inhibited NF-rB-target gene expression
and phosphorylation of IjBa and P65. Oxidative stress activates
NF-rB in different cell types [39,40], however, TNF-a-induced
ROS release through complex I and complex III of the mitochon-
drial respiratory chain leading to NF-rB-activation in liver cells
has not been previously shown. In addition, enhanced cellular
migration in liver cells was dependent on the activation of NF-rB,
as shown by the use of a speciﬁc NF-rB-activation inhibitor. NF-
rB-dependent cell migration was reported by several groups [41],
highlighting the key role of NF-rB activation in the development
of cancer, including HCC.
Increased ROS production is observed at different stages of liver
disease and in HCC. In addition, enhanced oxidative stress due to
TNF-a expression in Kupffer cells bears a major clinical problem
in the course of hepatic ischemia/reperfusion injury [42]. Here,
we show that TNF-a-induced mitochondrial ROS is released by
complex I and/or complex III of the mitochondrial respiratory
chain in liver cells. Furthermore, TNF-a-induced ROS production
enhances cellular migration through the activation of NF-rB signal-
ling elucidating a major ROS-dependent signalling cascade initi-
ated by the pro-inﬂammatory cytokine TNF-a in liver cells
(Fig. 5B). Our ﬁndings suggest that TNF-a-induced ROS signalling
in liver cells may constitute a therapeutic target occurring during
inﬂammation, hepatic ischemia/reperfusion injury and cancer.
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